title: Angiotensin II and the adrenal.
abstract: 1. Angiotensin II (AngII) evokes a variety of physiological responses in the adrenal gland. It is the major regulator of aldosterone secretion, in the medulla it enhances catecholamine release and it exerts trophic effects in the adrenal and stimulates growth factor secretion. 2. Angiotensin II acts via binding to specific receptors, located on the plasma membrane. Two pharmacologically distinct AngII receptor subtypes, type 1 (AT1) and type 2 (AT2) receptors, have been identified using the non-peptide antagonists Dup753 and PD 123177, respectively, and cDNA encoding each type have been identified. 3. In the adrenal, the AT1 receptor modulates all the known biological effects of AngII. The expression of the AT1 receptor is modulated at the mRNA and protein levels by many factors: conditions that increase levels of AngII (low sodium diet, renovascular hypertension, AngII infusion) up-regulate AT1 receptor mRNA levels and binding and increase aldosterone secretion. 4. A tissue renin-angiotensin system has been found in the adrenal, suggesting an important paracrine role for AngII in aldosterone regulation. 5. The possible involvement of AT1 receptors in human disease has been investigated by examining the role of AngII receptors in adrenal tumours. Binding and gene expression studies have shown that AngII receptors are abundantly expressed in aldosterone-producing adenoma (APA). 6. Densitometric analysis of AT1 expression in APA showed no significant differences compared with normal and non-tumorous adrenal. In addition, no mutations in the coding sequence of the AT1 receptor have been found to date in adrenal tumours.
authors.affiliation: Division of Endocrinology, University of Ancona, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Giacchetti
authors.forename: G
authors.initials: G
authors.lastname: Opocher
authors.forename: R
authors.initials: R
authors.lastname: Sarzani
authors.forename: A
authors.initials: A
authors.lastname: Rappelli
authors.forename: F
authors.initials: F
authors.lastname: Mantero
mesh_terms: D000236:Adenoma / Q000378:metabolism; D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism; D000313:Adrenal Medulla / Q000187:drug effects / Q000378:metabolism; D000450:Aldosterone / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001667:Binding, Competitive; D015152:Blotting, Northern; D002462:Cell Membrane / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011945:Receptors, Angiotensin / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects; D015854:Up-Regulation; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D018076:DNA, Complementary; D012333:RNA, Messenger; D011945:Receptors, Angiotensin; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D000450:Aldosterone